Immunome vs Marker Therapeutics
IMNM and MRKR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMNM and MRKR compare
Immunome is the larger company, worth 147 times as much as Marker Therapeutics ($2.1B against $14.5M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMNM | MRKR |
|---|---|---|
| Size and price | ||
| Market cap | $2.1B | $14.5M |
| Share price | $18.77 | $0.870 |
| Change, 1 year | 7.7% | −7.8% |
| Change, 5 years | 9.1% | −93.3% |
| Beta (5Y) | 1.74 | 1.27 |
| Employees | 177 | 5 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 531× | – |
| P/B | 4.7× | 1.2× (better) |
| FCF yield | −9.6% | – |
| Growth | ||
| Revenue growth (TTM) | −63.3% | – |
| Revenue growth, 5Y average | – | 48.0% |
| Profitability | ||
| Operating margin | −5948% | – |
| Net margin | −5594% | – |
| FCF margin | −5119% | – |
| Return on equity | −62.5% (better) | −76.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.66 (better) | 6.03 |
| Altman Z-score | 21.85 (better) | −42.38 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 23.8% |
| Held by insiders | 6.4% | 31.9% |
| Insider net buying, 12 months | −$25.2M | – |
| Short interest, % of float | 15.2% | 1.6% |
Go deeper
- IMNM stock overview
- IMNM income statement
- IMNM valuation and score
- MRKR stock overview
- MRKR income statement
- MRKR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.